Diabetes therapies in renal impairment

Clifford J. Bailey, Caroline Day

Research output: Contribution to journalArticlepeer-review


Depending on age, duration of diabetes and glycaemic control, 20-40% of patients with type 2 diabetes will incur a moderate or severe deterioration of renal function. This will impact the choice of blood glucose-lowering therapy and require more frequent monitoring of both renal function and glycaemic control. Moderate renal impairment (glomerular filtration rate 30-<60 ml/min) requires consideration of dose reduction or treatment cessation for metformin, glucagon-like peptide-1 receptor agonists, some sulphonylureas and some dipeptidyl peptidase-4 inhibitors. At lower rates of glomerular filtration down to about 15 ml/min it may be appropriate to use a meglitinide, pioglitazone or certain sulphonylureas with careful consideration of dose and co-morbidities. Dipeptidyl peptidase-4 inhibitors can be used at reduced dose in patients with very low rates of glomerular filtration, and linagliptin can be used without dose reduction, and has been used in patients on dialysis. Insulin can be used at any stage of renal impairment, but the regimen and the dose must be suitably adjusted and accompanied by adequate monitoring.
Original languageEnglish
Pages (from-to)167-171
Number of pages5
JournalBritish Journal of Diabetes and Vascular Disease
Issue number4
Publication statusPublished - Jul 2012


  • Albuminuria
  • type 2 diabetes
  • renal impairment
  • kidney disease
  • drug therapy


Dive into the research topics of 'Diabetes therapies in renal impairment'. Together they form a unique fingerprint.

Cite this